Intermittent exposure to doxorubicin <i>in vitro </i> selects for multifactorial non‐P‐glycoprotein‐associated multidrug resistance in RPMI 8226 human myeloma cells
Beat Wyler(Kantonsspital St. Gallen), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Beat M. Frey(Swiss Red Cross), Peter R. Twentyman(MRC Cancer Unit), Rik J. Scheper(Unknown), Erasmus Schneider, Ying Shao(Kantonsspital St. Gallen), Frank Gieseler(University Hospital Schleswig-Holstein), Luzius Schmid(University of St.Gallen), Maurizio Cianfriglia(Istituto Superiore di Sanità)
Cited by 24
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
|Proceedings of the National Academy of Sciences|1994|691
The drug resistance-related protein LRP is the human major vault protein
|Nature Medicine|1995|619